Home Drug IndexClinical Monograph

Cetirizine Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antihistamine

Subclass

Second-generation H1-receptor antagonist (piperazine derivative)

Speciality

Allergy & Immunology

Schedule (India)

Unscheduled (OTC) for single-ingredient oral formulations; Some FDCs may be Schedule H

Routes

Oral

Formulations

Form	Strengths Available
Tablets (film-coated)	5 mg, 10 mg
Dispersible/Orodispersible tablets	5 mg, 10 mg
Oral solution/Syrup	5 mg/5 mL (1 mg/mL)
Paediatric oral drops	10 mg/mL (1 mg = 2 drops approximately)

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Allergic Rhinitis (Seasonal and Perennial)

Parameter	Recommendation
Starting dose	10 mg once daily orally
Titration	Not applicable
Usual maintenance dose	10 mg once daily
Maximum dose	10 mg/day
Clinical notes	Onset of action within 30–60 minutes; duration of action 24 hours; evening dosing preferred if daytime sedation occurs; effective for sneezing, rhinorrhoea, nasal pruritus, and ocular symptoms

2. Chronic Spontaneous Urticaria (Chronic Idiopathic Urticaria)

Parameter	Recommendation
Starting dose	10 mg once daily orally
Titration	Not applicable at standard dosing
Usual maintenance dose	10 mg once daily
Maximum dose	10 mg/day (standard); up to 20 mg/day under specialist supervision (off-label)
Duration	Continue until symptoms resolve; reassess periodically (every 3–6 months)
Clinical notes	First-line therapy for chronic urticaria; may require several weeks for full effect in chronic urticaria

3. Allergic Conjunctivitis

Parameter	Recommendation
Starting dose	10 mg once daily orally
Titration	Not applicable
Usual maintenance dose	10 mg once daily
Maximum dose	10 mg/day
Clinical notes	Effective for itching, redness, and lacrimation associated with allergic conjunctivitis; may be combined with topical antihistamines or mast cell stabilisers for additional benefit

4. Acute Urticaria / Allergic Skin Reactions

Parameter	Recommendation
Starting dose	10 mg once daily orally
Titration	Not applicable
Usual maintenance dose	10 mg once daily
Maximum dose	10 mg/day
Duration	Until resolution of symptoms (usually 1–2 weeks)
Clinical notes	Can be used for pruritus associated with allergic dermatoses; adjunct to specific treatment of underlying cause

5. Pruritus Associated with Atopic Dermatitis (Symptomatic Relief)

Parameter	Recommendation
Starting dose	10 mg once daily orally (evening preferred)
Titration	Not applicable
Usual maintenance dose	10 mg once daily
Maximum dose	10 mg/day
Clinical notes	Provides symptomatic relief of itch; does NOT treat underlying eczema; use as adjunct to topical therapy; less sedating than first-generation antihistamines; evening dosing may help with nocturnal pruritus

Secondary Indications — Adults (Off-label)

Indication	Dose	Duration	Evidence	Notes
Chronic urticaria (refractory) — Updosing	10 mg twice daily (20 mg/day)	Reassess after 2–4 weeks	EAACI/GA²LEN guidelines; Indian dermatology specialist practice	OFF-LABEL; Specialist only; use when standard dose inadequate after 2–4 weeks; step up before adding other agents
Cold urticaria	10–20 mg/day	Continuous during cold season	Case series; specialist practice	OFF-LABEL; May require higher doses
Dermographism (symptomatic urticaria)	10–20 mg/day	Long-term as needed	Clinical experience	OFF-LABEL; Specialist only
Insect bite hypersensitivity	10 mg once daily	5–7 days or until resolved	Clinical practice	Standard use in many settings
Pre-procedure prophylaxis (contrast media reactions)	10 mg orally 1 hour before + 10 mg 12 hours before procedure	Single event	Indian radiology protocols	Combined with corticosteroids in high-risk patients

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

⚠️ Age and Safety Statement

Minimum age for approved use: 6 months (for allergic rhinitis and chronic urticaria)
Below 6 months: NOT recommended; use only in exceptional circumstances under specialist paediatric supervision
Safety monitoring: Watch for paradoxical excitability, sedation, feeding difficulties in infants

Primary Paediatric Indications

1. Allergic Rhinitis

Age Group	Formulation	Starting Dose	Titration	Maintenance Dose	Maximum Dose
6–12 months	Oral drops or syrup	2.5 mg once daily	Not applicable	2.5 mg once daily	2.5 mg/day
1–2 years	Oral drops or syrup	2.5 mg once daily	May divide into 1.25 mg BD if better tolerated	2.5 mg once daily (or divided)	2.5 mg/day
2–6 years	Syrup or chewable	2.5 mg once daily	May increase to 2.5 mg BD or 5 mg once daily	2.5–5 mg/day	5 mg/day
6–12 years	Tablet or syrup	5 mg once daily	May increase to 10 mg once daily or 5 mg BD	5–10 mg/day	10 mg/day
≥12 years	Tablet	10 mg once daily	Not applicable	10 mg once daily	10 mg/day

2. Chronic Urticaria

Age Group	Formulation	Starting Dose	Titration	Maintenance Dose	Maximum Dose
6–12 months	Oral drops or syrup	2.5 mg once daily	Not applicable	2.5 mg once daily	2.5 mg/day
1–2 years	Oral drops or syrup	2.5 mg once daily	Not applicable	2.5 mg/day	2.5 mg/day
2–6 years	Syrup	2.5 mg once daily	May increase to 5 mg/day (2.5 mg BD)	2.5–5 mg/day	5 mg/day
6–12 years	Tablet or syrup	5 mg once daily	May increase to 10 mg once daily	5–10 mg/day	10 mg/day
≥12 years	Tablet	10 mg once daily	Not applicable	10 mg once daily	10 mg/day

3. Acute Allergic Reactions / Pruritus

Same age-based dosing as above
Duration: Usually 5–7 days or until symptoms resolve
Reassess if symptoms persist beyond 2 weeks

Administration Notes (Paediatric)

Oral drops: Can be administered directly into mouth or mixed with small amount of water; administer immediately after mixing
Syrup: Use calibrated measuring device; do not use household spoons
Evening dosing: Preferred if any sedation noted

Safety Monitoring in Paediatrics

Monitor for excessive sedation, especially in infants
Watch for paradoxical hyperactivity/irritability (more common in young children)
Assess hydration if vomiting or feeding difficulties occur
Renal function consideration in children with kidney disease

Secondary Paediatric Indications (Off-label)

Indication	Age	Dose	Duration	Notes
Atopic dermatitis (pruritus control)	>6 months	Age-appropriate standard dose	During flares; not long-term	OFF-LABEL; Limited evidence for eczema-specific benefit; symptomatic relief only
Viral exanthem-associated pruritus	>6 months	Age-appropriate dose	3–5 days	Common clinical practice; symptomatic relief

Renal Adjustments

Cetirizine is predominantly renally excreted; dose adjustment required:

eGFR (mL/min/1.73 m²)	Dose Recommendation
>50	No adjustment required
30–50	5 mg once daily
10–<30	5 mg every alternate day
<10 or ESRD on dialysis	Avoid if possible; not effectively removed by dialysis

Hepatic adjustment

Contraindications

Known hypersensitivity to cetirizine, hydroxyzine, levocetirizine, or other piperazine derivatives
Severe renal impairment (eGFR <10 mL/min) unless under close specialist monitoring
History of acute urinary retention
Hypersensitivity to any excipients in the formulation

Cautions

Mild to moderate renal impairment — dose adjustment required
Epilepsy or conditions lowering seizure threshold
Prostatic hypertrophy or bladder outlet obstruction
Concurrent use of CNS depressants (opioids, benzodiazepines, alcohol)
Elderly patients — increased risk of sedation, falls, and urinary retention
Occupations requiring alertness (driving, operating machinery) — advise caution despite being "non-sedating"

Pregnancy

Parameter	Details
Risk category	Relatively safe; no major teratogenicity reported in human data
Preferred alternative	First trimester: Chlorpheniramine if sedating agent is acceptable
When may be used	Second and third trimester when benefit outweighs risk; commonly used in clinical practice
Monitoring	Maternal sedation/dizziness; use minimum effective dose

Lactation

Parameter	Details
Compatibility	Compatible with breastfeeding
Drug levels in milk	Low (estimated <0.5% of maternal dose reaches infant)
Preferred alternative	Loratadine (considered equally safe, possibly less sedating)
Infant monitoring	Drowsiness, irritability, feeding difficulty (rare)

Elderly

Parameter	Recommendation
Starting dose	5 mg once daily
Titration	Slower titration recommended; reassess after 3–5 days
Special risks	Increased sedation, dizziness, fall risk, urinary retention, cognitive effects
Renal consideration	Assess eGFR before initiation; many elderly have unrecognised renal impairment

Major drug interactions

Drug/Class	Effect	Recommendation
Alcohol	Additive CNS depression; marked sedation	Avoid concomitant use
Other CNS depressants (benzodiazepines, opioids)	Enhanced sedation and psychomotor impairment	Avoid or use with close monitoring
Hydroxyzine	Cross-sensitivity; potential for cumulative antihistaminic effects	Avoid switching without adequate washout period
High-dose theophylline (>400 mg/day)	May reduce cetirizine clearance by ~16%	Monitor for increased sedation

Moderate drug interactions

Drug/Class	Effect	Recommendation
Anticholinergic drugs (TCAs, oxybutynin, hyoscine)	Additive anticholinergic effects — dry mouth, urinary retention, constipation	Use together cautiously; monitor symptoms
Macrolide antibiotics (azithromycin, erythromycin)	May slightly increase cetirizine plasma levels	Usually not clinically significant; no dose change needed
Ketoconazole, itraconazole	Mild increase in cetirizine exposure	Monitor for sedation; usually tolerated
First-generation antihistamines	Increased sedation without additional efficacy	Avoid concurrent use

Common Adverse effects

Somnolence / drowsiness (more common than other second-generation agents)
Headache
Dry mouth
Fatigue
Pharyngitis (especially in children)
Abdominal discomfort
Dizziness

Serious Adverse effects

Adverse Effect	Notes
Anaphylaxis / angioedema	Rare; discontinue immediately and manage as emergency
Seizures	Rare; particularly in children with predisposition or febrile illness
Hepatic dysfunction	Rare; consider periodic LFTs in chronic high-dose use
Urinary retention	In predisposed patients (prostatic hypertrophy, anticholinergic co-medication)
Paradoxical CNS stimulation	Agitation, hyperactivity — more common in young children

Monitoring requirements

Phase	Parameter
Baseline	Renal function (especially in elderly, chronic users); hepatic function if concern exists
After initiation	Assess for sedation, paradoxical agitation (children), urinary symptoms
Long-term (>30 days)	Periodic renal function; screen for adverse effects; reassess ongoing need

Brands in India

Alerid (Cipla)
Cetzine (GSK/Zydus)
Cetcip (Cipla)
Okacet (Lupin)
Zyncet (Sanofi)
Zyrtec (Johnson & Johnson — less commonly stocked)
Allercet (Alkem)

Fixed-Dose Combinations (FDCs):

Cetirizine + Montelukast: Montair-LC (Cipla), Levocet-M (Glenmark), Montek LC (Sun Pharma)

Price range (INR)

Formulation	Approximate Price
Tablet 10 mg (per tablet)	₹0.90–₹3.00
Tablet 5 mg (per tablet)	₹0.60–₹2.00
Syrup 60 mL	₹20–₹45
Drops 15 mL	₹35–₹60
FDC with Montelukast (per tablet)	₹5–₹12

Widely available as generics and branded generics
Not under NLEM price control as a single agent

Clinical pearls

Evening dosing preferred — despite being labelled "non-sedating," cetirizine causes more drowsiness than loratadine or fexofenadine in some patients
Rapid onset — symptom relief begins within 30–60 minutes; suitable for acute allergic episodes
Dose doubling in urticaria — up to 20 mg/day may be used OFF-LABEL in refractory chronic urticaria under specialist care
Pregnancy and lactation — safer option compared to first-generation antihistamines; can be used when indicated
Renal impairment — unlike loratadine/fexofenadine, cetirizine requires dose reduction; always check eGFR in elderly
Paediatric use — weight-based dosing essential in young children; avoid below 6 months unless specialist-supervised

Version

RxIndia v1.0 — 02 Jun 2025

Reference

CDSCO approved product inserts
Indian Pharmacopoeia
API Textbook of Medicine
ICMR Guidelines on Allergy Management
AIIMS Paediatric Drug Formulary
IAP Paediatric Dosing Guidelines
Indian Dermatology Practice Protocols
WHO Model Formulary (supportive for paediatric dosing)
EAACI/GA²LEN Urticaria Guidelines (for off-label high-dose evidence only)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...